Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03590119 | Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases(LUTIA) | completed | Phase 2 / Phase 3 | 26 | Marnix LamOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03722511 | Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs | completed | Phase 2 | 10 | Lowell Anthony, MDOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02608203 | [68 Ga]-DOTANOC PET/CT in GEP-NETs(GEP-NOC) | completed | Phase 2 / Phase 3 | 18 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02651987 | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg(CLARINET FORTE) | completed | Phase 2 | 99 | IpsenINDUSTRY | 10 | Oct 3, 2022 | clinicaltrials |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | completed | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT02358356 | Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study(CONTROL NETS) | completed | Phase 2 | 75 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03271281 | PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 | completed | Phase 2 | 113 | Rigshospitalet, DenmarkOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT03278275 | PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 | completed | Phase 2 | 116 | Rigshospitalet, DenmarkOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT04552847 | Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors | completed | Phase 2 / Phase 3 | 85 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04318561 | Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors(PET) | completed | Phase 1 / Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02838342 | Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors(EPICentro) | completed | Phase 2 | 28 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT02939651 | A Study of Pembrolizumab in Patients With Neuroendocrine Tumors | completed | Phase 2 | 21 | Fox Chase Cancer CenterOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT02441062 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | completed | Phase 2 | 122 | Sue O'DorisioOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00326469 | Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours | completed | Phase 2 | 30 | IpsenINDUSTRY | 1 | Nov 5, 2020 | clinicaltrials |
| NCT02420691 | Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02698410 | Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.(ATLANT) | completed | Phase 2 | 40 | IpsenINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT02575300 | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04129255 | Octreotide LAR in the Induction of Immunologic Response in NENs Patients(CSMS99) | completed | Phase 2 | 34 | National Cancer Institute, NaplesOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02402062 | A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours | completed | Phase 2 | 17 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT02067988 | Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study(HEPAR_Plus) | completed | Phase 2 | 34 | UMC UtrechtOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT04296149 | Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe(RADIONET) | completed | Phase 2 | 5 | European Institute of OncologyOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00939523 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | completed | Phase 2 | 9 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00501540 | Lithium for Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT01967537 | Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors | completed | Phase 2 | 341 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01456078 | A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors(ILUMINET) | completed | Phase 2 | 60 | Lund University HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT00781911 | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01280201 | Pazopanib as Single Agent in Advanced NETs | completed | Phase 2 | 44 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT01283542 | Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.(Passion I) | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT00605566 | Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors | completed | Phase 2 | 22 | University Health Network, TorontoOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00688623 | RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe(RAMSETE/CDE16) | completed | Phase 2 | 73 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 25, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01435122 | A Study of Axitinib in Advanced Carcinoid Tumors | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT02279602 | Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study | completed | Phase 2 | 7 | Mateon TherapeuticsINDUSTRY | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT02299089 | Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | completed | Phase 2 | 12 | Camurus ABINDUSTRY | 4 | Dec 15, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Nov 8, 2022source: clinicaltrials